OWL Metabolomics is a biotechnology company with the mission to identify biomarkers and therapeutic targets in the field of high prevalence diseases. The company is focused in the area of human health, with pioneering applications in the international scientific arena, and its goal is to identify, validate, patent and commercialize diagnosis and/or prognosis systems, as well as therapeutic targets. Its technological platform offers metabolomics and lipidomics services to Pharma, Biotech companies, Research Centers and Food Companies. To consolidate the developments of OWL as a technology-based company, an innovative line of development has been developed, Metabolomics, which allows opening diagnostics to the massive identification of specific biomarkers for a given pathology. Currently there are two business lines: In vitro serum based Non Alcoholic Fatty Liver Disease (NAFLD) diagnosis test. Metabolomics and lipidomics services to pharmaceutical, biotechnology companies, research centers and food industries in key areas such as biomarkers discovery, clinical studies, diagnostics, toxicology, companion diagnostics development and food biomarkers.